Light-sensitive ion-passing molecules

Patent metadata

Field	Value
Publication number	US-9249234-B2
Application number	US-201213622809-A
Country	US
Kind code	B2
Filing date	Sep 19, 2012
Priority date	Mar 17, 2010
Publication date	Feb 2, 2016
Grant date	Feb 2, 2016

Abstract

The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.

First claim

What is claimed is:

1. A light-activated protein comprising, in order from amino terminus (N-terminus) to carboxyl terminus (C-terminus):
a) a core amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:4;
b) an endoplasmic reticulum (ER) export signal; and
c) a membrane trafficking signal.

2. The light-activated protein of claim 1 , wherein the ER export signal comprises the amino acid sequence FCEYENEV (SEQ ID NO:12).

3. The light-activated protein of claim 1 , wherein the membrane trafficking signal comprises the amino acid sequence KSRITSEGEYIPLDQIDINV (SEQ ID NO:11).

4. The light-activated protein of claim 1 , wherein the core amino acid sequence is at least 95% identical to amino acids 25-265 of SEQ ID NO:2.

5. The light-activated protein of claim 1 , wherein the core amino acid sequence is at least 95% identical to SEQ ID NO:3.

6. The light-activated protein of claim 1 , wherein the core amino acid sequence is at least 95% identical to SEQ ID NO:4.

7. An isolated polynucleotide comprising a nucleotide sequence encoding the light-activated protein of claim 1 .

8. The polynucleotide of claim 7 , wherein the light-activated protein-encoding nucleotide sequence is operably linked to a promoter.

9. The polynucleotide of claim 7 , wherein the promoter is a CaMKIIa promoter.

10. The polynucleotide of claim 7 , wherein the promoter is a synapsin I promoter.

11. The polynucleotide of claim 7 , wherein the polynucleotide is in an expression vector.

12. The polynucleotide of claim 11 , wherein the expression vector is a viral vector.

13. The polynucleotide of claim 12 , wherein the viral vector is an adenoassociated virus vector, a retroviral vector, an adenoviral vector, a herpes simplex virus vector, or a lentiviral vector.

Assignees

• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Zhang Feng
• Gradinaru Viviana

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A01K2207/05

  Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A01K2227/105

  Murine · CPC title

• A61N2005/0663

  Coloured light · CPC title